#USA #Biopharmaceutical #Bethlehem #ABEC #ATB™-2100

ABEC Unveils the ATB™-2100 for Advanced Therapy Manufacturing

Introduction

In a groundbreaking announcement, ABEC, a leader in engineering solutions for biopharmaceutical manufacturing, has introduced the ATB™-2100. This innovative system marks a significant step forward in cell and gene therapy production, offering unprecedented scalability, reproducibility, and automation. As the demand for advanced therapies continues to rise globally, the ATB™-2100 aims to transform how these therapies are developed and produced.

What is the ATB™-2100?

The ATB™-2100 is a state-of-the-art cell expansion system that utilizes a closed, automated platform tailored to meet the rigorous demands of cell and gene therapy applications. It has been explicitly engineered for challenging applications, such as the expansion of T lymphocytes, induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and other emerging modalities. This system not only ensures efficient cell growth but also integrates seamlessly from preclinical development through to commercial production.

Innovative Technology Behind ATB™-2100

At the heart of this revolutionary platform is ABEC's exclusive hollow fiber perfusion membrane network. This intricate system continuously supplies nutrients and gases necessary for cell growth while effectively removing metabolic waste, mimicking the human circulatory system. The low shear environment created by diffusion is ideally suited for promoting optimal cell growth, thus achieving exceptionally high cell densities and viability rates. Unlike other expansion technologies that often require process redevelopments during scale-up, the ATB™-2100 maintains a constant membrane surface-to-volume ratio across bioreactor volumes ranging from 200 mL to 10 L. This unique capability allows for a direct and straightforward transition of process conditions from initial development to commercial production.

Benefits of the ATB™-2100

The ATB™-2100 addresses significant challenges in the cell and gene therapy space. Traditional methods often encounter hurdles that can stall upscaling and increase costs, ultimately delaying commercialization. By offering unparalleled scalability and reducing development timelines, the ATB™-2100 dramatically minimizes risks during technology transfers, facilitating a faster time-to-market for life-saving therapies.

Scott Pickering, CEO of ABEC, commented, "Cell and gene therapies face substantial development and manufacturing challenges that limit scalability, inflate costs, and hinder timely commercialization. The ATB™-2100 overcomes these obstacles and signifies a major advancement that revolutionizes the industry."

Conclusion

With over 50 years of expertise in biopharmaceutical manufacturing, ABEC continues to pioneer innovations that enhance productivity and accelerate the market entry of life-changing therapies. The launch of the ATB™-2100 is a testament to ABEC's commitment to providing comprehensive engineering solutions that support the entire lifecycle of biopharmaceutical production.

For more information about the ATB™-2100 advanced bioreactor platform, visit www.abec.com or contact [email protected].

About ABEC

ABEC is a world-leading provider of engineering solutions and services dedicated to biopharmaceutical manufacturing. With a legacy of innovation, ABEC combines its expertise in bioprocess equipment, engineering, automation, and manufacturing support to assist in developing and commercializing therapies that improve lives. From R&D to commercial implementation and lifecycle support, ABEC delivers the innovative solutions necessary to enhance productivity and global manufacturing success.